) Osteosarcoma is the most common malignant bone tumor in children. Approximately 80 percent of patients present with non-metastatic disease. After the diagnosis is made by a biopsy, treatment involves 3-4 courses of neoadjuvant chemotherapy before definitive surgery, followed by post-operative chemotherapy. With currently available treatment, approximately 30-40 percent of patients with non-metastatic disease relapse after therapy. There is no prognostic factor that can be used at the time of diagnosis to predict which patients will have a high risk of relapse. The only significant prognostic factor predicting the outcome in a patient with non-metastatic osteosarcoma is the histopathologic response of the primary tumor resected at the time of definitive surgery. The degree of necrosis in the primary tumor is a reflection of the tumor response to neoadjuvant chemotherapy. Higher degree of necrosis is associated with lower risk of relapse and therefore better outcome. Patients with lower degree of necrosis have a much higher risk of relapse and poor outcome even after complete resection of the primary tumor. Unfortunately this poor outcome cannot be altered despite modification of post-operative chemotherapy to account for the resistance of the primary tumor to neoadjuvant chemotherapy. Thus there is an urgent need to identify prognostic factors that can be used at the time of diagnosis to recognize the subtypes of osteosarcomas patients that have high risk of relapse so that more appropriate chemotherapy can be used at the outset to improve the outcome. We propose to establish a molecular classification system to distinguish such subsets of osteosarcoma based on their gene expression profiles. This project will be a collaboration among several institutions including the Texas Children's Cancer Center, Baylor College of Medicine, Pediatric Oncology Branch, NCI, Cancer Genetics Branch, NHGRI, Biometric Research Branch, NCI and Incyte Pharmaceuticals, Inc. We plan to recruit 100 osteosarcoma patients who are receiving the same therapy through a treatment protocol. Using cDNA microarrays, we will investigate the gene expression profiles of the tumor tissues at the time of biopsy and definitive surgery. These profiles will be correlated with clinical outcome. In addition, we also plan to compare the gene expression profiles of the primary tumor and those of the metastatic lesions.
The specific aims are: 1. To validate and optimize cDNA microarray technology for gene expression profiling of clinical specimens. 2. To establish the relevant gene expression profiles for molecular classification of osteosarcoma by correlating these profiles with clinical outcome, chemosensitivity, and metastatic potential.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA088126-01
Application #
6196582
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (M1))
Program Officer
Jacobson, James W
Project Start
2001-04-01
Project End
2005-03-31
Budget Start
2001-04-01
Budget End
2002-03-31
Support Year
1
Fiscal Year
2001
Total Cost
$571,522
Indirect Cost
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Li, Yiting; Flores, Ricardo; Yu, Alexander et al. (2011) Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer 117:207-17
Lau, Ching C (2009) Molecular classification of osteosarcoma. Cancer Treat Res 152:459-65
Ma, Ou; Cai, Wei-Wen; Zender, Lars et al. (2009) MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 69:2559-67
Rabin, Karen; Man, Tsz-Kwong; Lau, Ching C (2008) Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program 62:173-85;discussion 185-8
Lu, Xin-Yan; Lu, Yaojuan; Zhao, Yi-Jue et al. (2008) Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res 6:937-46
Man, Tsz-Kwong; Chintagumpala, Murali; Visvanathan, Jaya et al. (2005) Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65:8142-50
Man, Tsz-Kwong; Lu, Xin-Yan; Jaeweon, Kim et al. (2004) Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4:45
Lau, Ching C; Harris, Charles P; Lu, Xin-Yan et al. (2004) Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39:11-21